These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 19523878)
1. Will CSF analysis become routine in people with memory complaints? Gauthier S Lancet Neurol; 2009 Jul; 8(7):595-6. PubMed ID: 19523878 [No Abstract] [Full Text] [Related]
2. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877 [TBL] [Abstract][Full Text] [Related]
3. [Biomarkers in cerebrospinal fluid and blood in memory complaints]. Zetterberg H; Andreasen N; Blennow K Lakartidningen; 2009 May 13-19; 106(20):1386-9. PubMed ID: 19585836 [No Abstract] [Full Text] [Related]
4. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538 [TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination. Ivanoiu A; Sindic CJ Neurocase; 2005 Feb; 11(1):32-9. PubMed ID: 15804922 [TBL] [Abstract][Full Text] [Related]
6. Preclinical AD predicts decline in memory and executive functions in subjective complaints. van Harten AC; Smits LL; Teunissen CE; Visser PJ; Koene T; Blankenstein MA; Scheltens P; van der Flier WM Neurology; 2013 Oct; 81(16):1409-16. PubMed ID: 24049134 [TBL] [Abstract][Full Text] [Related]
7. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR; Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049 [TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Snider BJ; Fagan AM; Roe C; Shah AR; Grant EA; Xiong C; Morris JC; Holtzman DM Arch Neurol; 2009 May; 66(5):638-45. PubMed ID: 19433664 [TBL] [Abstract][Full Text] [Related]
9. White matter lesion severity is associated with reduced cognitive performances in patients with normal CSF Abeta42 levels. Stenset V; Hofoss D; Johnsen L; Skinningsrud A; Berstad AE; Negaard A; Reinvang I; Gjerstad L; Fladby T Acta Neurol Scand; 2008 Dec; 118(6):373-8. PubMed ID: 18510598 [TBL] [Abstract][Full Text] [Related]
10. CSF levels of beta-amyloid 1-42, tau and phosphorylated tau protein in CADASIL. Formichi P; Parnetti L; Radi E; Cevenini G; Dotti MT; Federico A Eur J Neurol; 2008 Nov; 15(11):1252-5. PubMed ID: 18803653 [TBL] [Abstract][Full Text] [Related]
12. Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. Jongbloed W; Kester MI; van der Flier WM; Veerhuis R; Scheltens P; Blankenstein MA; Teunissen CE Alzheimers Dement; 2013 May; 9(3):276-83. PubMed ID: 23110867 [TBL] [Abstract][Full Text] [Related]
13. Markers of Alzheimer's disease in a population attending a memory clinic. Frisoni GB; Prestia A; Zanetti O; Galluzzi S; Romano M; Cotelli M; Gennarelli M; Binetti G; Bocchio L; Paghera B; Amicucci G; Bonetti M; Benussi L; Ghidoni R; Geroldi C Alzheimers Dement; 2009 Jul; 5(4):307-17. PubMed ID: 19560101 [TBL] [Abstract][Full Text] [Related]
14. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Buerger K; Ewers M; Andreasen N; Zinkowski R; Ishiguro K; Vanmechelen E; Teipel SJ; Graz C; Blennow K; Hampel H Neurology; 2005 Nov; 65(9):1502-3. PubMed ID: 16275849 [No Abstract] [Full Text] [Related]
15. Biomarkers for Alzheimer's disease. The research advances incrementally, but clinical use is still years away. Harv Ment Health Lett; 2010 Nov; 27(5):1-3. PubMed ID: 21218612 [No Abstract] [Full Text] [Related]
16. Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Kester MI; Boelaarts L; Bouwman FH; Vogels RL; Groot ER; van Elk EJ; Blankenstein MA; van der Flier WM; Scheltens P Dement Geriatr Cogn Disord; 2010; 29(6):491-7. PubMed ID: 20523047 [TBL] [Abstract][Full Text] [Related]
17. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Herukka SK; Hallikainen M; Soininen H; Pirttilä T Neurology; 2005 Apr; 64(7):1294-7. PubMed ID: 15824371 [TBL] [Abstract][Full Text] [Related]
18. Biomarkers in subjects with amnestic mild cognitive impairment. Maruyama M; Arai H; Ootsuki M; Matsui T; Sasaki H; Yamazaki T; Kaneta T; Okamura T J Am Geriatr Soc; 2003 Nov; 51(11):1671-2. PubMed ID: 14687403 [No Abstract] [Full Text] [Related]
19. Levels of ApoE in cerebrospinal fluid are correlated with Tau and 24S-hydroxycholesterol in patients with cognitive disorders. Shafaati M; Solomon A; Kivipelto M; Björkhem I; Leoni V Neurosci Lett; 2007 Sep; 425(2):78-82. PubMed ID: 17822846 [TBL] [Abstract][Full Text] [Related]